FORM PTO 1449 (modified)					ATTY DOCKET NO. 01997.033600.4	APPLICATION NO. 09/714,792					
LIST	OF REFE	EPARTMENT OF COM T AND TRADEMARK ERENCES CITED BY	APPLICANT(S)	25	APPLICANT Mary Collins et al.						
(Use several sheets if necessary) SEP 1 3 2004			FILING DATE November 16, 2000		GROUP 1647						
			To to the	<u>Z</u>	U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
					· · · · · · · · · · · · · · · · · · ·			<u>-</u> -			
											
	FOREIGN PATENT DOCUMENTS										
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT			
								·-			
							ļ				
) (Including Author, Title, Date, Pertinent Pages, Etc.)						
		Husain, et al., "Interleukin-13 Receptor as a Unique Target for Anti-Glioblastoma Therapy", <i>Int. J. Cancer</i> , Vol. 92 (2001), pages 168-175									
FH		Barth, "hIL-13 PE38QQR NeoPharm", <i>Current Opinion in Investigational Drugs</i> , Vol. 2, No. 9 (2001), pages 1309-1313									
FH		Li, et al., "Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein <i>in vitro</i> and <i>in vivo</i> in nude mice", <i>Protein Engineering</i> , Vol. 15, No. 5 (2002), pages 419-427									
FH		Husain, et al., "Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside", <i>Journal of Neuro-Oncology</i> , Vol. 65 (2003), pages 37-48									
FH		Mintz, et al., "Molecular targeting with recombinant cytotoxins of interleukin-13 receptor α2-expressing glioma", <i>Journal of Neuro-Oncology</i> , Vol. 64 (2003), pages 117-123									
EXAMINER	fice	. 11	md		DATE CONSIDERED 1130	DC					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sneet		or _	_1_
-------	--	------	-----